FDA
-
-
-
-
-
-
-
Kissei Pharmaceutical warns against new TAVNEOS prescriptions amid safety concerns
-
-
-
-
-
-
-
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
-
-
-
-
-
-
-
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
-
-
-
-
-
-
-
FDA grants full approval for Amgen's IMDELLTRA in lung cancer
-
-
-
-
-
-
-
AstraZeneca's Tezspire gets FDA approval for nasal polyp condition
-
-
-
-
-
-
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
-
-
-
-
-
-
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
-
327,397 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

